Session » (2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 2017

Baseline and 2-year Follow-up of Pulmonary Function Among CTD-ILD Subtypes

10:30AM-12:30PM: Abstract Number: 2028

Behçet’s Syndrome Beyond Endemic Borders: A 24-Year Longitudinal Analysis of Mortality in a Diverse South American Cohort

10:30AM-12:30PM: Abstract Number: 2021

Can Colchicine Be a Therapeutic Option for Patients with Ankylosing Spondylitis?

10:30AM-12:30PM: Abstract Number: 2029

Characteristics of a Historical Cohort of Adult Patients with Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 2051

Clinical Burden of Illness Among Patients with Immunoglobulin-G4-Related Disease in the United States

10:30AM-12:30PM: Abstract Number: 2026

Clinical Features and Treatment Outcomes in Aseptic Abscess Syndrome: A Systematic Review of 104 Cases

10:30AM-12:30PM: Abstract Number: 2015

Clinical features of IgG4-related disease – a single centre experience

10:30AM-12:30PM: Abstract Number: 2022

Clinical Predictors of Macrophage Activation Syndrome and Treatment Outcomes in Adult-Onset Still’s Disease: A 24-Year Single-Center Experience

10:30AM-12:30PM: Abstract Number: 2033

Complement Fragments are Deposited in the Submandibular Glands in IgG4-Related Disease

10:30AM-12:30PM: Abstract Number: 2048

DDR2 auto-phosphorylation in patients with Warburg-Cinotti syndrome promotes differentiation of fibroblasts into myofibroblasts and expansion of immature B cells with antibody production.

10:30AM-12:30PM: Abstract Number: 2049

Descriptive Analysis of a Cohort of Neurosarcoidosis Mimics

10:30AM-12:30PM: Abstract Number: 2027

Development of a multi-disease panel for autoimmune diseases

10:30AM-12:30PM: Abstract Number: 2016

Effectiveness of Nintedanib combined with different DMARDs in joint and pulmonary domains of Rheumatoid Arthritis – Interstitial Lung Disease. National multicenter study of 74 patients

10:30AM-12:30PM: Abstract Number: 2050

Efficacy and Safety of Antifibrotic Therapy in Autoimmune–Associated Interstitial Lung Disease: A Meta-Analysis

10:30AM-12:30PM: Abstract Number: 2041

Evaluating Biologic Effectiveness in Co-Occurring Dermatologic and Rheumatic Disease: A Systematic Review

10:30AM-12:30PM: Abstract Number: 2034

Hidden Burden in Rheumatology: Cross-Sectional Study of Hearing Loss in Systemic Autoimmune Diseases

10:30AM-12:30PM: Abstract Number: 2019

Incidence of Coronavirus Disease 2019 in Participants with IgG4-Related Disease Treated with Inebilizumab in the MITIGATE Study

10:30AM-12:30PM: Abstract Number: 2020

Inebilizumab Efficacy and Safety in Patients with Common, Urgent, and Fibrotic Organ Manifestations of IgG4-RD: Subgroup Analyses from the MITIGATE Trial

10:30AM-12:30PM: Abstract Number: 2044

Infections and Associated Mortality in VEXAS Syndrome: A Systematic Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 2035

Interim Phase 1 Results for SPY002, a Novel Half-Life Extended Monoclonal Antibody Targeting TL1A, Suggest A Potential for Q3M or Q6M Maintenance Dosing for Rheumatologic Disease

10:30AM-12:30PM: Abstract Number: 2018

Investigating Epidemiology, Clinical associations, and Outcomes of Uveitis: A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 2023

Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center

10:30AM-12:30PM: Abstract Number: 2036

JAK1 selective inhibitors versus pan-JAK inhibitors: comparative real-world study of drug retention in chronic inflammatory arthritis

10:30AM-12:30PM: Abstract Number: 2030

Krebs von den Lungen 6 levels (∆KL6) is a reliable marker of disease activity and response to therapy in CTD-ILD

10:30AM-12:30PM: Abstract Number: 2045

Malignancy in Behçet’s Syndrome: A 24-Year Cohort Study In a Non-Endemicand Multiethnic Country

10:30AM-12:30PM: Abstract Number: 2031

Management of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases: A Comparison of Rheumatologist and Pulmonologist Perspectives

10:30AM-12:30PM: Abstract Number: 2024

Racial Disparities in Outcomes Among Patients With Neuromyelitis Optica: A Global Population-Based Study

10:30AM-12:30PM: Abstract Number: 2038

Real-World Use of Dual Targeted Therapy in Rheumatic Disease: A Single-Center Case Series

10:30AM-12:30PM: Abstract Number: 2043

Renal Outcomes of Long-term Canakinumab in Patients with Adult Familial Mediterranean Fever (FMF) and Biopsy-Confirmed AA Amyloidosis

10:30AM-12:30PM: Abstract Number: 2042

Safety and Effectiveness of the Use of Combined Therapy with bDMARDS and tsDMARDs in Immune-mediated Inflammatory Diseases

10:30AM-12:30PM: Abstract Number: 2025

Spectrum of Autoantibodies in CNS Demyelinating Diseases: Clinical, Laboratory and Imaging Associations

10:30AM-12:30PM: Abstract Number: 2040

Steroid Psychosis and Neuropsychiatric Symptoms induced by Corticosteroid Injection in Rheumatology Patients

10:30AM-12:30PM: Abstract Number: 2037

The Largest International Cohort Study of HA20 Reveals Novel Genetic Architecture and Age-Dependent Phenotypic Evolution

10:30AM-12:30PM: Abstract Number: 2039

To Hold or Not to Hold: Variability in Management of DMARDs in the Setting of Acute Infections – A Survey of Rheumatologists

10:30AM-12:30PM: Abstract Number: 2047

Trends in Lung Transplant Listing Outcomes in Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) Across Two Decades

10:30AM-12:30PM: Abstract Number: 2046

Utilization of the All of Us Research Program to Study the Impact of Genetic Background on Autoinflammatory Diseases

10:30AM-12:30PM: Abstract Number: 2032

Validation of systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS 10) in adult patients with Still’s Disease

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].